ALGONQUIN trial: what clinicians have said so far
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
- NCT03715478 ↗
- Active, not recruiting
- Canadian Myeloma Research Group
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on ALGONQUIN (belantamab mafodotin plus pomalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 21 indexed sources
Automated from all 21 indexed sources (Sep 2022 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether less frequent belantamab dosing keeps response depth while reducing ocular events
- Whether single-arm results reflect patient selection rather than benefit over a historical control
- Whether prior anti-CD38 refractoriness or triple-class refractory status changes benefit from belantamab-pomalidomide-dexamethasone
- Whether γδ T-cell expansion and T-cell receptor repertoire can identify who responds to belantamab
Indexed commentary on ALGONQUIN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X, typically up to 48 once built | |
| 6 YouTube videos, typically up to 26 once built | |
| 4 podcast episodes, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination With Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- GSK2857916 with Pomalidomide and Dexamethasone
- Arms
- GSK2857916 with Pomalidomide and Dexamethasone · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- Recommended Phase 2 Dose (RP2D)
- Overall Response Rate (ORR)
- Sponsor
- Canadian Myeloma Research Group with GlaxoSmithKline
- Start
- Nov 26, 2018
- Primary completion
- Jun 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03715478 · updated Oct 22, 2026
Publications
linked from the registry- Trudel S, McCurdy A, Louzada ML, Parkin S, White D, Chu MP, Kotb R, Mian H, Othman I, Su J, Khan A, Gul E, Reece D. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nat Med. 2024 Feb;30(2):543-551. doi: 10.1038/s41591-023-02703-y. Epub 2024 Jan 4. PubMed 38177852